Seaport Therapeutics, Inc.

Seaport Therapeutics is a drug development company working on medicines for depression and anxiety. The company uses a technology platform called Glyph to create new versions of existing drugs that work better when taken as pills. Its main experimental drug, GlyphAllo, is designed to treat postpartum depression, while a second drug candidate, GlyphAgo, targets anxiety and depression. The company was founded in 2024 and is based in Boston.